Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 15, 2025

OVCAR-4

RRID:CVCL_1627
Type: Cell Line

Proper Citation

(RRID:CVCL_1627)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1627

Proper Citation: (RRID:CVCL_1627)

Sex: Female

Defining Citation: PMID:1348364, PMID:2041050, PMID:2307530, PMID:3335022, PMID:3930572, PMID:6372095, PMID:6385258, PMID:7718330, PMID:9041185, PMID:10700174, PMID:12080474, PMID:12960427, PMID:15748285, PMID:17088437, PMID:19372543, PMID:20164919, PMID:22068913, PMID:22336246, PMID:22347499, PMID:22384151, PMID:22460905, PMID:22628656, PMID:23839242, PMID:23856246, PMID:23933261, PMID:24023729, PMID:24279929, PMID:24670534, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26589293, PMID:27235858, PMID:27377824, PMID:27397505, PMID:27807467, PMID:28196595, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:32612269, PMID:35839778

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: Metabolome analysis., Omics: lncRNA expression profiling., Omics: Fluorescence phenotype profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: CNV analysis., Omics: Array-based CGH., Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: OVCAR-4

Synonyms: OVCAR 4, NIH:OVCAR-4, NIH:OVCAR4, OVCAR.4, OVCAR4, Ovcar4

Cross References: BTO:BTO_0002561, CLO:CLO_0037096, EFO:EFO_0005442, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03472889, BioSample:SAMN10987768, cancercelllines:CVCL_1627, Cell_Model_Passport:SIDM00092, ChEMBL-Cells:CHEMBL3307517, ChEMBL-Targets:CHEMBL614051, Cosmic:688105, Cosmic:875860, Cosmic:897434, Cosmic:905990, Cosmic:974295, Cosmic:1044240, Cosmic:1092624, Cosmic:1175884, Cosmic:1305313, Cosmic:1312355, Cosmic:1436034, Cosmic:1998466, Cosmic-CLP:905990, DepMap:ACH-000617, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905990, GEO:GSM2174, GEO:GSM50220, GEO:GSM50284, GEO:GSM185137, GEO:GSM185138, GEO:GSM186442, GEO:GSM186443, GEO:GSM743475, GEO:GSM743494, GEO:GSM750829, GEO:GSM784572, GEO:GSM799364, GEO:GSM799427, GEO:GSM847107, GEO:GSM844669, GEO:GSM844670, GEO:GSM851935, GEO:GSM887484, GEO:GSM888565, GEO:GSM1153436, GEO:GSM1181279, GEO:GSM1181286, GEO:GSM1374801, GEO:GSM1670318, GEO:GSM2124646, IARC_TP53:21085, IARC_TP53:21126, IARC_TP53:30217, LiGeA:CCLE_876, LINCS_LDP:LCL-1697, Millipore:SCC258, NCI-DTP:OVCAR-4, PharmacoDB:OVCAR4_1218_2019, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1627, PubChem_Cell_line:CVCL_1627, SKY/M-FISH/CGH:2817, Wikidata:Q54937010

ID: CVCL_1627

Record Creation Time: 20250131T202204+0000

Record Last Update: 20250131T204022+0000

Ratings and Alerts

No rating or validation information has been found for OVCAR-4.

No alerts have been found for OVCAR-4.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. Cancer research, 84(15), 2403.

Spirtos AN, et al. (2024) RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells. bioRxiv : the preprint server for biology.

Zhang Y, et al. (2024) Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma. Cancer research communications, 4(12), 3165.

Mishra AK, et al. (2024) Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer. Cell reports, 43(4), 114041.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Aljardali MW, et al. (2024) Nucleolar Localization of the RNA Helicase DDX21 Predicts Survival Outcomes in Gynecologic Cancers. Cancer research communications, 4(6), 1495.

Narayanan A, et al. (2024) A novel ITGB8 transcript variant sustains ovarian cancer cell survival through genomic instability and altered ploidy on a mutant p53 background. Journal of ovarian research, 17(1), 218.

Handley KF, et al. (2023) Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma. Gynecologic oncology, 173, 114.

Brubaker LW, et al. (2023) Novel chromobox 2 inhibitory peptide decreases tumor progression. Expert opinion on therapeutic targets, 1.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.

Glassman D, et al. (2023) Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. iScience, 26(2), 106020.

Salvi A, et al. (2023) PAX8 modulates the tumor microenvironment of high grade serous ovarian cancer through changes in the secretome. Neoplasia (New York, N.Y.), 36, 100866.

Javellana M, et al. (2022) Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer. Cancer research, 82(1), 169.

Yamamoto TM, et al. (2022) Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. Molecular cancer therapeutics, 21(4), 647.

AbuEid M, et al. (2022) Fluorinated triphenylphosphonium analogs improve cell selectivity

and in vivo detection of mito-metformin. iScience, 25(12), 105670.

Cumin C, et al. (2022) Glycosphingolipids are mediators of cancer plasticity through independent signaling pathways. Cell reports, 40(7), 111181.

Handley KF, et al. (2021) Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Molecular cancer therapeutics, 20(12), 2352.

Palavalli Parsons LH, et al. (2021) Identification of PARP-7 substrates reveals a role for MARylation in microtubule control in ovarian cancer cells. eLife, 10.

Zavareh RB, et al. (2021) HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins. Cell chemical biology, 28(2), 158.

Tailor D, et al. (2021) Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. Cell chemical biology, 28(8), 1206.